Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;40(7):1026-1037.
doi: 10.1007/s10875-020-00844-0. Epub 2020 Aug 15.

The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999-2019)

Affiliations

The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999-2019)

Vassilios Lougaris et al. J Clin Immunol. 2020 Oct.

Abstract

Primary immunodeficiencies (PIDs) are heterogeneous disorders, characterized by variable clinical and immunological features. National PID registries offer useful insights on the epidemiology, diagnosis, and natural history of these disorders. In 1999, the Italian network for primary immunodeficiencies (IPINet) was established. We report on data collected from the IPINet registry after 20 years of activity. A total of 3352 pediatric and adult patients affected with PIDs are registered in the database. In Italy, a regional distribution trend of PID diagnosis was observed. Based on the updated IUIS classification of 2019, PID distribution in Italy showed that predominantly antibody deficiencies account for the majority of cases (63%), followed by combined immunodeficiencies with associated or syndromic features (22.5%). The overall age at diagnosis was younger for male patients. The minimal prevalence of PIDs in Italy resulted in 5.1 per 100.000 habitants. Mortality was similar to other European registries (4.2%). Immunoglobulin replacement treatment was prescribed to less than one third of the patient cohort. Collectively, this is the first comprehensive description of the PID epidemiology in Italy.

Keywords: Primary immunodeficiencies; patient registry.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
PID registration in the IPINet registry. Annual numbers for new (white bars) and patients registered the year before (N-1) (black bars) for the period 1999–2019
Fig. 2
Fig. 2
Regional minimal prevalence of PIDs in Italy. Geographic distribution of PIDs in the Italian territory based on patients’ residence (data refer to 2019). Darker shades of gray areas correspond to higher minimal prevalence of PIDs. Data are expressed as minimal prevalence calculated per 105 inhabitants
Fig. 3
Fig. 3
PID distribution and characteristics in the IPINet registry. a Overall PID distribution in Italy (percentages) based on the latest IUIS classification (2019). b Detailed PIDs’ distribution in the IPINet registry (number of patients). Patterns identify six groups based on the latest IUIS classification
Fig. 4
Fig. 4
Death rate of PID patients in the IPINet registry. a Number and percentages of alive, deceased, and lost to follow-up patients during the 20-year follow-up period (patients lost to follow-up patients without updated data in the registry over the years). b Comparison of IPINet PID death percentages with previously published PID registries of other countries (Italy: black; Europe: gray; other countries: light gray). Parentheses next to each country name correspond to number of patients followed by year of analysis (number of patients; year of analysis)
Fig. 5
Fig. 5
Minimal prevalence of PIDs in Italy and comparison with other countries. Comparison of minimal prevalence of PIDs in Italy calculated on alive patients with previously published data from other PID registries (Italy: black; Europe: gray; other countries: light gray). Parentheses next to each country name correspond to number of patients followed by year of analysis (number of patients; year of analysis)

References

    1. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Commitee. J Clin Immunol. 2020;40:24–64. doi: 10.1007/s10875-019-00737-x. - DOI - PMC - PubMed
    1. Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40(1):66–81. doi: 10.1007/s10875-020-00758-x. - DOI - PMC - PubMed
    1. Montserrat A, Taruscio D. Policies and actions to tackle rare diseases at European level. Ann Ist Super Sanita. 2019;55(3):296–304. - PubMed
    1. Groft SC, Posada de la Paz M. Rare diseases: joining mainstream research and treatment based on reliable epidemiological data. Adv Exp Med Biol. 2017;1031:3–21. doi: 10.1007/978-3-319-67144-4_1. - DOI - PubMed
    1. Matamoros FN, Llambi JM, Boren TE, Borja SR, Casariego GF. Primary immunodeficiency syndrome in Spain: first report of the national registry in children and adults. J Clin Immunol. 1997;17:333–339. doi: 10.1023/A:1027382916924. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources